



Ireland Query: Reimbursement of epinephrine (Epipen®) autoinjector

Purpose of the query:

- To ascertain reimbursement prices of epinephrine auto-injector (Epipen®) in other jurisdictions and any reimbursement controls/validations in place
- Application for a price increase received from supplier (Viatris) for adult and paediatric presentations
- 50% uplift in PTW requested, Budget Impact of €850,000, €1.2 million across all brands of epinephrine autoinjectors
- Essential medicine – emergency medicine used in anaphylaxis
- Stock also held by community pharmacy contractors for vaccination services where ampoules are not available
- 3 alternative product portfolios available – Viatris brand 55% market share
- Shortages previously in this area – potential interruption of supply to the Irish market

Number of answers received:

- 11 countries responded

Results of PPRI query:

- 8 countries - higher unit prices than ROI
- 2 countries - marginally lower unit prices than ROI
- 1 country - not reimbursed
- 1 country – limitations on number of auto injectors per dispensing
- 1 country – reimbursable under certain conditions. Continuations of treatment only with documentation of the allergy

Possible Impact:

- Provided contextual information to support national decision making.
- Price increase request approved for the totality of the epinephrine market.